| hyp-SDA-2026-04-08-g | Oligodendrocyte Stress Response Uniformity | 0.46 | 0.50 | EIF2AK3 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Iron Dysregulation as Convergent Pathomechanism | 0.46 | 0.50 | GPX4 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Spinal Cord Microglia Activation State Convergence | 0.46 | 0.50 | CX3CR1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Spinal Cord Astrocyte Reactivity Convergence | 0.46 | 0.50 | STAT3 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Spinal Vascular Unit Breakdown as Universal Driver | 0.46 | 0.50 | VEGFA | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Sphingosine-1-Phosphate Gradient Disruption | 0.46 | 0.50 | S1PR1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Complement Cascade as Final Common Effector | 0.46 | 0.50 | C5AR1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Glymphatic System Disruption | 0.46 | 0.50 | AQP4 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Temporal Window Specificity | 0.46 | 0.50 | TNF | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | CNS-Peripheral Cytokine Compartmentalization | 0.46 | 0.50 | LRP1 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Astrocyte-Neuron Metabolic Coupling | 0.46 | 0.50 | SLC16A7 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Microglial State-Dependent Cytokine Function | 0.46 | 0.50 | TREM2 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Synaptic Plasticity Preservation | 0.46 | 0.50 | TNFRSF1B | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Compensatory Cytokine Network Activation | 0.46 | 0.50 | NLRP3 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Sphingolipid Metabolism Rebalancing | 0.46 | 0.50 | SMPD1 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Lactate Shuttle Pathway Enhancement | 0.46 | 0.50 | SLC16A1 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Mitochondrial Contact Site Stabilization | 0.46 | 0.50 | VDAC1 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Purinergic-Metabolic Coupling Restoration | 0.46 | 0.50 | P2RY12 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Lipid Droplet Dynamics as Therapeutic Lever | 0.46 | 0.50 | DGAT1 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis | 0.46 | 0.50 | MTOR | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | NAD+ Salvage Pathway Optimization | 0.46 | 0.50 | NAMPT | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Light-Independent Chronopharmacology | 0.46 | 0.50 | CSNK1D/CSNK1E | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Microglial-Specific Circadian Gene Therapy | 0.46 | 0.50 | ARNTL | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Clock Gene-Mediated Microglial Reprogramming | 0.46 | 0.50 | ARNTL/CLOCK | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Circadian Extracellular Matrix Remodeling | 0.46 | 0.50 | MMP9/HAS2 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | REV-ERB Agonist Microglial Deactivation | 0.46 | 0.50 | NR1D1/NR1D2 | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Circadian Metabolic Reprogramming Therapy | 0.46 | 0.50 | SIRT1/PRKAA1/PPARGC1A | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Temporal Cytokine Receptor Modulation | 0.46 | 0.50 | IL1R1/TNFRSF1A | active | 2026-04-27 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-04-f | Synaptic Vesicle Protein Phosphorylation Reprograms Release Probability and Inte | 0.46 | 0.50 | SYN1 (Synapsin-1) | active | 2026-04-27 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| hyp-SDA-2026-04-04-f | Synaptic Mitochondrial Proteostasis Collapse Disrupts ATP-Demand Coupling at Act | 0.46 | 0.50 | PPID (Cyclophilin D) | active | 2026-04-27 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| hyp-SDA-2026-04-04-f | Cdk5/p25-PSD-95 Phosphorylation Disrupts Synaptic Scaffolding and Shifts APP Pro | 0.46 | 0.50 | PSD-95 (DLG4) | active | 2026-04-27 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| hyp-sda-2026-04-01-g | RNA Granule Phase Separation as Transient Cross-Seeding Hub | 0.46 | 0.50 | TARDBP | active | 2026-04-27 | sda-2026-04-01-gap-9137255b |
| hyp-sda-2026-04-01-g | Membrane Lipid Composition-Dependent Specificity Switch Enabling Cross-Seeding R | 0.46 | 0.50 | PLD3 | active | 2026-04-27 | sda-2026-04-01-gap-9137255b |
| hyp-sda-2026-04-01-g | Galectin-3 as Damage-Sensor Scaffold for Multimeric Cross-Seeding at Compromised | 0.46 | 0.50 | LGALS3 | active | 2026-04-27 | sda-2026-04-01-gap-9137255b |
| h-ae924ee8 | C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction via Microglial-Neuron | 0.46 | 0.50 | C1QA/C1QB/C1QC | proposed | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260411-082509-118fcb37 |
| h-e165e0e6 | PGC1α Activation in PV+ Interneurons Bypasses Mitophagy Deficit to Restore Gamma | 0.46 | 0.50 | PPARGC1A | proposed | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260411-082509-118fcb37 |
| h-f78067ba | GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ Oligomerization See | 0.45 | 0.50 | ST3GAL5 | proposed | 2026-04-25 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-69acbe8b | P2X7 Receptor Antagonism to Block ATP-Induced Microglial Pyroptosis | 0.45 | 0.45 | P2RX7 (P2X7 receptor) → PANX1 → NLRP3 → Caspase-1/Gasdermin | proposed | 2026-04-25 | SDA-2026-04-16-frontier-immunomics-e6f97b29 |
| h-var-7b37ca6d98 | SREBP-2 Upstream Modulation for APOE4 Lipidation Enhancement | 0.45 | 0.38 | SREBP-2/SCAP | promoted | 2026-04-21 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| h-var-6856106f48 | Mitochondrial Damage-Triggered SPP1 Inflammasome Coupling | 0.45 | 0.39 | SPP1 | promoted | 2026-04-21 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| h-645cc2de | TREM2-SYK Signaling Axis Couples OxPC Recognition to Phagocytic Clearance | 0.45 | 0.65 | TREM2 (Triggering receptor expressed on myeloid cells 2) + S | proposed | 2026-04-13 | SDA-2026-04-13-gap-pubmed-20260410-165345-41805e1b |
| h-3ae038e731 | Age-dependent downregulation of KPNA2 creates limbic neuron-specific nuclear imp | 0.45 | 0.45 | KPNA2 (karyopherin α2) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf |
| h-404bab00 | Age-Stratified Ketone Dosing Matrix | 0.45 | 0.20 | OXCT1 | proposed | 2026-04-16 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| h-0c68c97b58 | Astrocyte Heterogeneity and Synapse-Specific Eat-Me Signal Expression | 0.45 | 0.40 | MFGE8, NPTX2 (Neuronal Pentraxin 1) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-00d4ef329d | SST-Microglial CRHR1-SSTR2 Neuroimmune Cross-Talk (Secondary Hypothesis) | 0.45 | 0.45 | CRHR1, SST, SSTR2; NF-κB, TNF-α | proposed | 2026-04-28 | SRB-2026-04-28-h-var-b7e4505525 |
| h-255db681 | HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis | 0.45 | 0.48 | HDAC6 | proposed | 2026-04-25 | SDA-2026-04-16-gap-epigenetic-adpdals |
| h-85753bf7db | HBOT at 2.0 ATA for 60 min, 5x/week for 6 weeks enhances hippocampal neurogenesi | 0.45 | 0.42 | BDNF | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-63ef3ee258 | Amyloid first impairs cholinergic terminals through alpha7 nicotinic receptor-de | 0.45 | 0.46 | APP, CHRNA7 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-e849205bca |
| h-8b269886b2 | α4β1 Integrin (VLA-4) and JAK/STAT Pathway | 0.45 | 0.50 | ITGA4, ITGB1 (α4β1 heterodimer), JAK1/JAK2, STAT3 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755 |
| h-945bac1144 | Metabolic Reprogramming Toward GAPDH Inhibition | 0.45 | 0.35 | GAPDH, HK2 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062150-a6cc7467 |